Status:

COMPLETED

Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso

Lead Sponsor:

Heidelberg University

Collaborating Sponsors:

Centre de Recherche en Sante de Nouna, Burkina Faso

Conditions:

Malaria

Eligibility:

All Genders

6-59 years

Phase:

PHASE2

Brief Summary

Design: Single-centre Indication: Malaria caused by Plasmodium falciparum Objectives: To determine and compare the efficacy of AQ treatment in young children with uncomplicated falciparum malaria in ...

Eligibility Criteria

Inclusion

  • Age 6-59 months
  • Uncomplicated falciparum malaria (axillary temperature ≥ 37.5°C and ≥ 2.000 P. falciparum asexual parasites per µl blood)
  • Written informed consent given by the parents/caretakers

Exclusion

  • Complicated or severe malaria (repeated vomiting, seizures or other neurological impairment, haemoglobin \< 7 g/dl or haematocrit \< 21%)
  • Any apparent significant disease (e. g. pneumonia, meningitis, hepatitis, severe diarrhoea, measles, severe malnutrition)
  • Malaria treatment with western drugs and/or antibiotics with anti malarial potency during last 7 days except chloroquine.

Key Trial Info

Start Date :

September 1 2005

Trial Type :

INTERVENTIONAL

End Date :

November 1 2005

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00261222

Start Date

September 1 2005

End Date

November 1 2005

Last Update

February 3 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre de Recherche en Santé de Nouna (CRSN)

Nouna, Burkina Faso, P.O. Box 34

Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso | DecenTrialz